Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 07, 2023 | June 09, 2023 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | June 04, 2021 | June 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Omega Therapeutics, Inc.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2033-06-06 | Direct | 18,118 |
Reported balance
After 2023-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 18,118 · Balance 18,118 F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
REGENXBIO Inc.
Report date June 04, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.52 · Expires 2031-06-04 | Direct | 10,000 |
Reported balance
After 2021-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest in 12 equal monthly installments following June 4, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in 12 equal monthly installments following June 4, 2021.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.03 · Expires 2030-12-23 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.93 · Expires 2024-03-06 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Disposition to issuer · Disposed 6,666 · Balance 0 F1: The exercise price of these options is $18.90 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD F2: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Deferred Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-17 · Disposition to issuer · Disposed 547,656.26 · Balance 0 F2: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F3: N/A |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of these options is $18.90 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD
F2: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
F3: N/A
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001213900-26-069243 · marketforms-73180.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001213900-25-054280 · marketforms-69807.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 22:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-24-051375 · marketforms-66258.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001213900-23-047470 · ownership.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000899243-23-015150 · doc4.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2033-06-06 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | PurchaseCommon Stock | 10,000 | $3.10 | $31,000.00 |
DisclosureSEC source: 0001213900-22-037266 · ownership.xml · nonDerivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,000 Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001213900-22-031989 · ownership.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:10 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021895 · doc4.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:37 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | PurchaseCommon Stock | 10,000 | $4.25 | $42,500.00 |
DisclosureSEC source: 0001209191-22-019238 · doc4.xml · nonDerivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,000 Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:37 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | PurchaseCommon Stock | 10,000 | $4.46 | $44,555.00 |
DisclosureSEC source: 0001209191-22-018478 · doc4.xml · nonDerivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,000 F1 · price: The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.28 to $4.50, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 18:30 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerDeferred Share Unit · Derivative | 547,656.26 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-141748 · tm2133436-4_4seq1.xml · derivative · entry 3 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 547,656.26 shares Expires not disclosed F2 · derivative.exercise_price: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F2 · price: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F2 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F3 · derivative.expiration_date: N/A Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 18:30 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,666 | $0.00 Strike: $14.93 | $0.00 |
DisclosureSEC source: 0001104659-21-141748 · tm2133436-4_4seq1.xml · derivative · entry 2 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,666 shares Expires 2024-03-06 F1 · derivative.exercise_price: The exercise price of these options is $18.90 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD F2 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 18:30 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001104659-21-141748 · tm2133436-4_4seq1.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires 2030-12-23 F2 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 17:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 52,941 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-030838 · doc4.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,941 Underlying: Common Stock · 52,941 shares Expires 2031-07-28 F1 · derivative.exercise_date: The options vest and become exercisable with respect to 25% of the underlying shares on June 2, 2022 and in 36 equal monthly installments thereafter such that the option will become fully vested and exercisable on June 22, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 00:01 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001209191-21-039680 · doc4.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001562180-21-004125 · primarydocument.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 4, 2021. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:31 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035843 · doc4.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001562180-20-004063 · primarydocument.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2020. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 168,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003221 · doc4.xml · nonDerivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 3/24th of the shares were vested upon grant and 1/24th of the shares vest monthly thereafter, beginning on February 10, 2020. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,491 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003221 · doc4.xml · derivative · entry 4 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,491 Underlying: Common Stock · 10,491 shares Expires 2029-04-28 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F8 · price: Received in the Merger in exchange for a stock option to acquire 55,000 shares of ArTara Sub common stock for $1.75 per share. F7 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 6,676 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003221 · doc4.xml · derivative · entry 3 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,676 Underlying: Common Stock · 6,676 shares Expires 2028-12-31 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F6 · price: Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share. F5 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 12,399 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003221 · doc4.xml · derivative · entry 2 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,399 Underlying: Common Stock · 12,399 shares Expires 2028-07-11 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F4 · price: Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share. F3 · derivative.exercise_date: The shares subject to this option shall vest in forty eight (48) approximately equal increments of one thousand one hundred forty five (1,145) whole Option Shares beginning on the first day of the first calendar month following July 12, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a "Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being April 1, 2023), all of the Option Shares which had not vested by then (being not less than 1,184 Option Shares) will vest and become exercisable. Read SEC document |
| January 09, 2020 Filed Jun 11, 2020 17:30 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 6,676 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-035842 · doc4a.xml · derivative · entry 2 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,676 Underlying: Common Stock · 6,676 shares Expires 2028-12-03 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F5 · price: Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share. F4 · derivative.exercise_date: The shares subject to this option shall vest in forty eight (48) approximately equal increments of one hundred thirty nine (139) whole Option Shares beginning on the first day of the first calendar month following December 4, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a "Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then (being not less than 139 Option Shares) will vest and become exercisable. Read SEC document |
| January 09, 2020 Filed Jun 11, 2020 17:30 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 12,399 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-035842 · doc4a.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,399 Underlying: Common Stock · 12,399 shares Expires 2028-07-11 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F3 · price: Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share. F2 · derivative.exercise_date: Seven hundred seventy-four (774) of the Option Shares shall vest as of October 1, 2018, and the remaining Option Shares shall vest in forty five (45) approximately equal increments of two hundred fifty eight (258) whole Option Shares beginning on the first day of the fourth calendar month following the date of the grant (being November 1, 2018) and then on the first day of each of the next forty four (44) months thereafter (each a "Vesting Date"), if the Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being July 1, 2022), all of the Option Shares which had not vested by then will vest and become exercisable, and that the vesting of all then unvested Option Shares shall be accelerated upon a Change of Control. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $43.02 | $0.00 |
DisclosureSEC source: 0001562180-19-003291 · primarydocument.xml · derivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2019. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,784 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-18-004775 · primarydocument.xml · derivative · entry 3 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 12,784 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 80,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 12,784 | $65.00 | $830,960.00 |
DisclosureSEC source: 0001562180-18-004775 · primarydocument.xml · nonDerivative · entry 2 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 12,784 | $3.76 | $48,067.84 |
DisclosureSEC source: 0001562180-18-004775 · primarydocument.xml · nonDerivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 716 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · derivative · entry 14 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,784 Underlying: Common Stock · 716 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 80,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · derivative · entry 13 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · derivative · entry 12 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2027-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following May 24, 2017. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,687 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · derivative · entry 11 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,687 shares Expires 2025-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 9,375 shares, became exercisable as follows: the option vested in nine equal monthly installments following September 16, 2015. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 883 | $0.00 Strike: $49.45 | $0.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · derivative · entry 10 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,292 Underlying: Common Stock · 883 shares Expires 2028-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vests in 12 equal monthly installments following May 25, 2018. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 18,786 | $65.03 | $1,221,653.58 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 8 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $65.00 to $65.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 716 | $3.76 | $2,692.16 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 7 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 6,250 | $12.74 | $79,625.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 6 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 6,250 | $18.85 | $117,812.50 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 5 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,687 | $22.00 | $103,114.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 4 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 883 | $49.45 | $43,664.35 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 3 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,721 | $0.00 Strike: $49.45 | $0.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · derivative · entry 9 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,175 Underlying: Common Stock · 1,721 shares Expires 2028-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vests in 12 equal monthly installments following May 25, 2018. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,721 | $65.00 | $111,865.00 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 2 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,721 | $49.45 | $85,103.45 |
DisclosureSEC source: 0001562180-18-004727 · primarydocument.xml · nonDerivative · entry 1 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · derivative · entry 16 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 13,500 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F10 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 80,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,988 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · derivative · entry 15 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 2,988 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F8 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,688 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · derivative · entry 14 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,687 Underlying: Common Stock · 4,688 shares Expires 2025-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F9 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 9,375 shares, became exercisable as follows: the option vested in nine equal monthly installments following September 16, 2015. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 21,176 | $60.38 | $1,278,606.88 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · nonDerivative · entry 10 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 13,500 | $3.76 | $50,760.00 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · nonDerivative · entry 9 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,988 | $12.74 | $38,067.12 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · nonDerivative · entry 8 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,688 | $22.00 | $103,136.00 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · nonDerivative · entry 7 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,262 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001562180-18-004643 · primarydocument.xml · derivative · entry 13 BESHAR LUKE M · CIK 0001192128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,238 Underlying: Common Stock · 3,262 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F8 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.